echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Non-invasive detection of GBM nanoparticle materials based on photoacoustic imaging technology

    Non-invasive detection of GBM nanoparticle materials based on photoacoustic imaging technology

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com







    Min Wu et al.
    of the Department of Chemical and Biomolecular Engineering of the National University of Singapore constructed nanoparticle TCFNP@iRGD for photoacoustic imaging of GBM in a mouse model derived from intracranial transplantation of glioma patients, and the material showed excellent GBM detection performance in vitro and in vivo.
    The results were published online in the September 2022 issue of Advanced Healthcare Materials
    .


    - Excerpted from the article chapter


    Ref: Wu M, et al.
    Adv Healthc Mater.
    2022 Nov; 11(21):e2201640.
    doi: 10.
    1002/adhm.
    202201640.
    Epub 2022 Sep 1.


    Research background




    CT and MRI are currently the main tools for clinical diagnosis of glioblastoma (GBM), but there are still disadvantages
    such as radiation risks and cumbersome procedures.

    As a non-invasive imaging mode, photoacoustic (PA) imaging can retain its strong optical contrast, height resolution and real-time visual advantages according to exogenous PA contrast agent, and become a potential GBM diagnostic method
    during preoperative operation.

    Min Wu et al.
    of the Department of Chemical and Biomolecular Engineering of the National University of Singapore constructed nanoparticle TCFNP@iRGD for photoacoustic imaging of GBM in a mouse model derived from intracranial transplantation of glioma patient cells (GPDCs), and the material showed excellent GBM detection performance in vitro and in vivo.
    The results were published online in the September 2022 issue of Advanced Healthcare Materials
    .


    Research methods



    The authors used nanoprecipitation combined with organic small molecule PA contrast agent [2-(3-cyano-4,5,5-trimethylfuran-2(5H)-subunit)malononitrile (TCF)-OH] to construct PA imaging nanomaterials (NPs) (TCFNP@iRGD).


    At the same time, in the in situ tumor-bearing mouse model of glioblastoma, MRI and PA imaging were used to image and compare
    the intracranial tumors of the model.


    Study results



    The results show that TCFNP synthesized by nanoprecipitation has similar physical properties to TCFNP@iRGD, including particle size and absorption peak
    .

    The PA signal generation performance of TCFNP@iRGD is concentration-dependent and has excellent photostability
    .



    The authors found that after incubation TCFNP@iRGD with GBM cells, red fluorescence from hyaluronic acid and green fluorescence from TMRMA-iRGD were exhibited, and the two fluorescence could be well combined, and tumor cells could successfully take up TCFNP@iRGD
    .

    The authors used tumor multicellular spheroid models (MCS) to further study the penetration of the material, and the results showed that iRGD modification can help NPs penetrate into the MCS core
    .


    The authors embedded 3D MCS cells in the gel and evaluated the PA signal by a real-time photoacoustic imaging system; It was found that the treated MCS cells TCFNP@iRGD had a stronger PA mapping signal
    than TCFNP.


    The results of fluorescence confocal microscopy showed that tumor cells had higher TCFNP@iRGD uptake than TCFNP, and showed concentration-dependent in the range of 2-5μg/mL, and the total uptake of TCFNP@iRGD cells was twice that of TCFNP, which proved that its tumor-specific accumulation characteristics were stronger
    .

    Finally, in the GPDC intracranial xenograft mouse model, the authors injected the material through the tail vein and imaged it by photoacoustic imaging system, and found that the PA signal intensity of the brain tumor region of the TCFNP@iRGD group was much higher than that of the TCFNP group, which proved that iRGD modification was given to brain tumor targeting performance and TCFNP@iRGD excellent PA imaging performance (Figure 1).


    Figure 1.
    TCFNP@iRGD in vivo PA imaging
    in GPDC intracranial xenograft mouse model.




    Conclusion of the study



    In summary, organic small molecule contrast agents were used to design and construct GBM tumor targeting material TCFNP@iRGD to achieve excellent performance
    in vivo and in vitro detection of GBM.

    As the first report on GBM photoacoustic imaging based on GPDC intracranial xenograft mouse model, this research result realizes the PA imaging performance of detecting GBM tumor specificity, which proves that the material has broad application potential
    in the clinical diagnosis of GBM.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.